最佳的滑膜巨细胞瘤（TGCT）的临床管理：来自专家社区的共识文件。
Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts.
发表日期：2023 Jan
作者：
Silvia Stacchiotti, Hans Roland Dürr, Inga-Marie Schaefer, Klaus Woertler, Rick Haas, Annalisa Trama, Augusto Caraceni, Jyoti Bajpai, Giacomo Giulio Baldi, Nicholas Bernthal, Jean-Yves Blay, Kjetil Boye, Javier-Martin Broto, Wei-Wu Tom Chen, Paolo Angelo Dei Tos, Jayesh Desai, Stephan Emhofer, Mikael Eriksson, Alessandro Gronchi, Hans Gelderblom, Jendrik Hardes, Wolfgang Hartmann, John Healey, Antoine Italiano, Robin L Jones, Akira Kawai, Andreas Leithner, Herbert Loong, Eric Mascard, Carlo Morosi, Nadine Otten, Emanuela Palmerini, Shreyaskumar R Patel, Peter Reichardt, Brian Rubin, Piotr Rutkowski, Claudia Sangalli, Kathrin Schuster, Beatrice M Seddon, Morena Shkodra, Eric L Staals, William Tap, Matt van de Rijn, Kirsten van Langevelde, Filip M M Vanhoenacker, Andrew Wagner, Lisette Wiltink, Sydney Stern, Van Michiel Van de Sande, Sebastian Bauer
来源：
CANCER TREATMENT REVIEWS
摘要：
关节滑囊滑膜巨细胞瘤（TGCT）是一种罕见的、局部侵袭性的间叶瘤，起源于关节、滑囊和肌腱鞘。TGCT包括结节型和弥漫型两种，前者表现为大多数温和的进展，后者表现为局部侵袭性行为。虽然通常不会危及生命，但TGCT可能会引起慢性疼痛，对功能和生命质量产生不利影响。CSFR1抑制剂具有缓解症状和提高生命质量的效果，但在大多数国家尚不可获得。在选择最合适的治疗方法时存在较大的不确定性，且缺乏TGCT的临床管理指南，这导致了全球新治疗方法的不一致应用，患者效果不佳。2022年6月，一次全球共识会议召开，涉及多个学科的专家和SPAGN的患者代表，以定义最佳的循证实践方法来优化TGCT的治疗，并产生了以下推荐。版权所有©2022作者。由Elsevier Ltd.出版。保留所有权利。
Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive, mesenchymal tumor arising from the joints, bursa and tendon sheaths. TGCT comprises a nodular- and a diffuse-type, with the former exhibiting mostly indolent course and the latter a locally aggressive behavior. Although usually not life-threatening, TGCT may cause chronic pain and adversely impact function and quality of life (QoL). CSFR1 inhibitors are effective with benefit on symptoms and QoL but are not available in most countries. The degree of uncertainty in selecting the most appropriate therapy and the lack of guidelines on the clinical management of TGCT make the adoption of new treatments inconsistent across the world, with suboptimal outcomes for patients. A global consensus meeting was organized in June 2022, involving experts from several disciplines and patient representatives from SPAGN to define the best evidence-based practice for the optimal approach to TGCT and generate the recommendations presented herein.Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.